Alnylam Pharmaceuticals (NASDAQ:ALNY) Coverage Initiated at Redburn Atlantic

Analysts at Redburn Atlantic started coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note issued to investors on Monday, MarketBeat reports. The firm set a “buy” rating and a $353.00 price target on the biopharmaceutical company’s stock. Redburn Atlantic’s target price suggests a potential upside of 38.02% from the company’s previous close.

Several other analysts have also recently issued reports on ALNY. Sanford C. Bernstein cut their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Stifel Nicolaus lifted their target price on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a “buy” rating in a research note on Monday. Scotiabank upped their target price on Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the stock a “sector outperform” rating in a report on Friday, March 21st. HC Wainwright raised their target price on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Monday, February 24th. Finally, Royal Bank of Canada upped their target price on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an “outperform” rating in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $316.25.

Alnylam Pharmaceuticals Trading Down 5.3 %

ALNY stock opened at $255.76 on Monday. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The company has a market capitalization of $33.27 billion, a PE ratio of -117.86 and a beta of 0.39. The company’s 50 day moving average price is $260.15 and its two-hundred day moving average price is $260.51. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 967 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the transaction, the chief financial officer now directly owns 32,786 shares of the company’s stock, valued at approximately $8,366,003.62. This trade represents a 2.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Yvonne Greenstreet sold 1,213 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the sale, the chief executive officer now directly owns 81,526 shares of the company’s stock, valued at $20,802,989.42. The trade was a 1.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock valued at $19,958,097 in the last 90 days. 1.50% of the stock is currently owned by insiders.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System boosted its position in shares of Alnylam Pharmaceuticals by 2.6% in the fourth quarter. California State Teachers Retirement System now owns 196,362 shares of the biopharmaceutical company’s stock worth $46,206,000 after purchasing an additional 5,037 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in shares of Alnylam Pharmaceuticals by 94.7% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 12,566 shares of the biopharmaceutical company’s stock worth $2,957,000 after purchasing an additional 6,112 shares in the last quarter. Lansforsakringar Fondforvaltning AB publ bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $10,011,000. Bannerman Wealth Management Group LLC purchased a new position in Alnylam Pharmaceuticals during the fourth quarter valued at $327,000. Finally, Siemens Fonds Invest GmbH increased its holdings in Alnylam Pharmaceuticals by 137.7% in the 4th quarter. Siemens Fonds Invest GmbH now owns 3,245 shares of the biopharmaceutical company’s stock valued at $764,000 after acquiring an additional 1,880 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.